SARM1 inhibitors, having demonstrated the ability to prevent axonal degeneration, are being evaluated for the treatment of a number of neurodegenerative disorders. Once approved, these therapies are likely to capture a significant market shareRoots Analysis has announced the addition of “SARM1 Inhibitors Therapeutics Market, 2022 – 2040”report to its list of offerings.
Presently, several SARM1 targeting therapy candidates are being developed by various industry players
About 65% of the pipeline candidates are currently being evaluated in the preclinical stages of development, followed by those currently in the discovery stage (35%). Further, it is worth mentioning that close to 85% of the SARM1 inhibitors are small molecules.
Currently, a number of companies claim to be engaged in the development of SARM1 inhibitors
The SARM1 inhibitors market is dominated by the presence of large companies (81%), followed by small players (19%). In addition, around 20% of the players were established post-2010.
120+ articles related to SARM1 inhibitors have been published between 2011 and 2022
Majority (81%) of the articles published in this domain were research papers, followed by review papers (12%). It is important to note that more than 70% of the total number of articles were published post-2018.
Over 30 grants have been awarded for research related to SARM1 inhibitors, since 2014
Close to 40% of the total amount was awarded under the R01 mechanism (which supports research projects). Further, genetics and neurology emerged as the key research departments, having received 34% of the total grants, each.
70+ patents related to SARM1 targeting therapeutics have been filed / granted till 2022
Over the years, the number of patents filed for SARM1 inhibitors has increased gradually; majority of the patents have been filed / granted in 2021. Most of the patents in this domain are patent applications (96%), followed by granted patents (3%).
North America is anticipated to capture more than 65% share of the market, by 2040
By 2040, the market revenues are likely to be driven by the sales of small molecules (95%) being developed as SARM1 inhibitors. Further, sales of therapeutics targeting multiple sclerosis are likely to contribute to a majority share (~40%) of revenues, in the long term.
To request a sample copy / brochure of this report, please visit
§ Who are the leading players engaged in the development of SARM1 targeting therapeutics?
§ What is the evolving trend of publications focused on SARM1 targeting therapeutics?
§ How is the intellectual property landscape in this field likely to evolve in the foreseen future?
§ What are the recent developments and strategic initiatives undertaken by players engaged in this market space related to the research and development of SARM1 targeting therapeutics?
§ What are the key value drivers that are likely to influence the evolution of this upcoming market?
§ How is the current and future market opportunity likely to be distributed across key market segments?
The financial opportunity within the SARM1 targeting therapeutics market has been analyzed across the following segments:
§ Type of Molecule
§ Small Molecules
§ Target Indication
§ Multiple Sclerosis
§ Peripheral, Central and Ocular Nervous System Disorders
§ Peripheral Neuropathies
§ Amyotrophic Lateral Sclerosis
§ Drug Developers
§ Company 1
§ Company 2
§ Company 3
§ Drug Candidates
§ Drug Candidate 1
§ Drug Candidate 2
§ Drug Candidate 3
§ Drug Candidate 4
§ Drug Candidate 5
§ Drug Candidate 6
§ Key Geographies
§ North America
The research includes detailed profiles of key players (listed below); featuring an overview of the company, financial information (if available), details related to its product portfolio, patent portfolio, recent developments (including partnerships and collaborations) and an informed future outlook.
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector.